152 related articles for article (PubMed ID: 29328399)
21. Effects of miR-193a and sorafenib on hepatocellular carcinoma cells.
Salvi A; Conde I; Abeni E; Arici B; Grossi I; Specchia C; Portolani N; Barlati S; De Petro G
Mol Cancer; 2013 Dec; 12():162. PubMed ID: 24330766
[TBL] [Abstract][Full Text] [Related]
22. Sorafenib inhibits macrophage-induced growth of hepatoma cells by interference with insulin-like growth factor-1 secretion.
Sprinzl MF; Puschnik A; Schlitter AM; Schad A; Ackermann K; Esposito I; Lang H; Galle PR; Weinmann A; Heikenwälder M; Protzer U
J Hepatol; 2015 Apr; 62(4):863-70. PubMed ID: 25463538
[TBL] [Abstract][Full Text] [Related]
23. Berberine, a natural plant alkaloid, synergistically sensitizes human liver cancer cells to sorafenib.
Huang Y; Wang K; Gu C; Yu G; Zhao D; Mai W; Zhong Y; Liu S; Nie Y; Yang H
Oncol Rep; 2018 Sep; 40(3):1525-1532. PubMed ID: 30015938
[TBL] [Abstract][Full Text] [Related]
24. Silencing activating transcription factor 2 promotes the anticancer activity of sorafenib in hepatocellular carcinoma cells.
Luo L; Cai L; Luo L; Tang Z; Meng X
Mol Med Rep; 2018 Jun; 17(6):8053-8060. PubMed ID: 29693700
[TBL] [Abstract][Full Text] [Related]
25. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
[TBL] [Abstract][Full Text] [Related]
26. Effects of low concentrations of regorafenib and sorafenib on human HCC cell AFP, migration, invasion, and growth in vitro.
Carr BI; D'Alessandro R; Refolo MG; Iacovazzi PA; Lippolis C; Messa C; Cavallini A; Correale M; Di Carlo A
J Cell Physiol; 2013 Jun; 228(6):1344-50. PubMed ID: 23169148
[TBL] [Abstract][Full Text] [Related]
27. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
Ou DL; Shen YC; Liang JD; Liou JY; Yu SL; Fan HH; Wang DS; Lu YS; Hsu C; Cheng AL
Clin Cancer Res; 2009 Sep; 15(18):5820-8. PubMed ID: 19737956
[TBL] [Abstract][Full Text] [Related]
28. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
Zhao D; Zhai B; He C; Tan G; Jiang X; Pan S; Dong X; Wei Z; Ma L; Qiao H; Jiang H; Sun X
Cell Signal; 2014 May; 26(5):1030-9. PubMed ID: 24486412
[TBL] [Abstract][Full Text] [Related]
29. Synergistic inhibitory effect of hyperbaric oxygen combined with sorafenib on hepatoma cells.
Peng HS; Liao MB; Zhang MY; Xie Y; Xu L; Zhang YJ; Zheng XF; Wang HY; Chen YF
PLoS One; 2014; 9(6):e100814. PubMed ID: 24956259
[TBL] [Abstract][Full Text] [Related]
30. [Tumor-associated macrophages promote the proliferation and migration as well as invasion of sorafenib-resistant hepatocellular carcinoma cells].
Wei X; Pu J; Guo Z; Li T; Zhu D; Wu Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2017 May; 33(5):617-622. PubMed ID: 28502299
[TBL] [Abstract][Full Text] [Related]
31. An artificial lncRNA targeting multiple miRNAs overcomes sorafenib resistance in hepatocellular carcinoma cells.
Tang S; Tan G; Jiang X; Han P; Zhai B; Dong X; Qiao H; Jiang H; Sun X
Oncotarget; 2016 Nov; 7(45):73257-73269. PubMed ID: 27689326
[TBL] [Abstract][Full Text] [Related]
32. Downregulation of Raf-1 kinase inhibitory protein as a sorafenib resistance mechanism in hepatocellular carcinoma cell lines.
Kim JS; Choi GH; Jung Y; Kim KM; Jang SJ; Yu ES; Lee HC
J Cancer Res Clin Oncol; 2018 Aug; 144(8):1487-1501. PubMed ID: 29858683
[TBL] [Abstract][Full Text] [Related]
33. 1118-20, an indazole diarylurea compound, inhibits hepatocellular carcinoma HepG2 proliferation and tumour angiogenesis involving Wnt/β-catenin pathway and receptor tyrosine kinases.
Lu YY; Wang JJ; Zhang XK; Li WB; Guo XL
J Pharm Pharmacol; 2015 Oct; 67(10):1393-405. PubMed ID: 26076716
[TBL] [Abstract][Full Text] [Related]
34. Sorafenib inhibits proliferation and invasion of human hepatocellular carcinoma cells via up-regulation of p53 and suppressing FoxM1.
Wei JC; Meng FD; Qu K; Wang ZX; Wu QF; Zhang LQ; Pang Q; Liu C
Acta Pharmacol Sin; 2015 Feb; 36(2):241-51. PubMed ID: 25557114
[TBL] [Abstract][Full Text] [Related]
35. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.
Lachenmayer A; Alsinet C; Savic R; Cabellos L; Toffanin S; Hoshida Y; Villanueva A; Minguez B; Newell P; Tsai HW; Barretina J; Thung S; Ward SC; Bruix J; Mazzaferro V; Schwartz M; Friedman SL; Llovet JM
Clin Cancer Res; 2012 Sep; 18(18):4997-5007. PubMed ID: 22811581
[TBL] [Abstract][Full Text] [Related]
36. Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice.
Chen Y; Huang Y; Reiberger T; Duyverman AM; Huang P; Samuel R; Hiddingh L; Roberge S; Koppel C; Lauwers GY; Zhu AX; Jain RK; Duda DG
Hepatology; 2014 Apr; 59(4):1435-47. PubMed ID: 24242874
[TBL] [Abstract][Full Text] [Related]
37. Sorafenib enhances proteasome inhibitor-mediated cytotoxicity via inhibition of unfolded protein response and keratin phosphorylation.
Honma Y; Harada M
Exp Cell Res; 2013 Aug; 319(14):2166-78. PubMed ID: 23727131
[TBL] [Abstract][Full Text] [Related]
38. Radiosensitivity enhancement of human hepatocellular carcinoma cell line SMMC-7721 by sorafenib through the MEK/ERK signal pathway.
Dai XF; Ding J; Zhang RG; Ren JH; Ma CM; Wu G
Int J Radiat Biol; 2013 Sep; 89(9):724-31. PubMed ID: 23682582
[TBL] [Abstract][Full Text] [Related]
39. Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling.
Wang H; Zhang C; Chi H; Meng Z
Int J Oncol; 2018 Jun; 52(6):2051-2060. PubMed ID: 29620259
[TBL] [Abstract][Full Text] [Related]
40. Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro.
Qu Z; Wu J; Wu J; Luo D; Jiang C; Ding Y
J Exp Clin Cancer Res; 2016 Sep; 35(1):159. PubMed ID: 27716356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
